Recently, it has been shown that the liver enhancement effect at the hepatobiliary phase of gadoxetic acid-enhanced MR imaging correlates with the Ctrough of paritaprevir, a NS3/4A protease inhibitor, and could predict the development of hyperbilirubinemia with an incident rate of 27% during an ombitasvir/paritaprevir/ritonavir regimen10. This evidence concerns the gene KRAS and Hyperbilirubinemia.